Abstract:Journal of Dental Research, Ahead of Print. RUNX2 is a master osteogenic transcription factor, and mutations in RUNX2 cause the inherited skeletal disorder cleidocranial dysplasia (CCD). Studies have revealed that RUNX2 is not only a downstream target of the bone morphogenetic protein (BMP) pathway but can also regulate the expression of BMPs. However, the underlying mechanism of the regulation of BMPs by RUNX2 remains unknown. In this project, we diagnosed a CCD patient with a 7.86-Mb heterozygous deletion on chromosome 6 containing all exons of RUNX2 by multiplex ligation-dependent probe amplification (MLPA) and whole-genome sequencing (WGS). Bone marrow mesenchymal stem cells (BMSCs) were further extracted from patient alveolar bone fragments (CCD-BMSCs), an excellent natural model to explore the possible mechanism. The osteogenic differentiation ability of CCD-BMSCs was severely affected by RUNX2 heterozygous deletion. Also, BMP4 decreased most in BMP ligands, and CHRDL1, a BMP antagonist, was abnormally elevated in CCD-BMSCs. Furthermore, BMP4 treatment essentially rescued the osteogenic capacity of CCD-BMSCs, and RUNX2 overexpression reversed the abnormal expression of BMP4 and CHRDL1. Notably, we constructed CRISPR/Cas9 Runx2+/m MC3T3-E1 cells, which simulated a variant in CCD-BMSCs, to exclude the interference of other gene deletions and the heterogeneity of the genetic background of primary cells, and verified all findings from the CCD-BMSCs. Moreover, the luciferase reporter experiment showed that RUNX2 could inhibit the transcription of CHRDL1. Through immunofluorescence, the inhibitory effect of CHRDL1 on BMP4/Smad signaling was confirmed in MC3T3-E1 cells. These results revealed that RUNX2 regulated the BMP4 pathway by inhibiting CHRDL1 transcription. We collectively identified a novel RUNX2/CHRDL1/BMP4 axis to regulate osteogenic differentiation and noted that BMP4 might be a valuable therapeutic option for treating bone diseases.

[Kleptomania: clinical characteristics and treatment].

Effect of Cleidocranial Dysplasia‐related Novel Mutation of RUNX2 on Characteristics of Dental Pulp Cells and Tooth Development

A Novel RUNX2 Mutation in Cleidocranial Dysplasia Patients.

Mutations in the RUNX2 Gene in Chinese Patients with Cleidocranial Dysplasia.

Business as usual? Changes in health care's workforce and organization of work.

RUNX2 mutation reduces osteogenic differentiation of dental follicle cells in cleidocranial dysplasia

Mutation Analysis of the RUNX2 Gene in a Family with Cleidocranial Dysplasia

Mutations in the RUNX2 gene in a patient with Cleidocranial Dysplasia

Identification of human dental follicle cells with RUNX2 gene mutation

Bounds of the incremental gain for discrete-time recurrent neural networks

RUNX2 Mutation Impairs 1Α,25-Dihydroxyvitamin D 3 Mediated Osteoclastogenesis in Dental Follicle Cells

Effect And Possible Mechanism Of Network Between Micrornas And Runx2 Gene On Human Dental Follicle Cells

Effect of the RUNX2 Gene Mutations on Subnuclear Localization of the RUNX2 Protein Mutants

A Study on the Ultrastructure of Hypocalcification in Patient with Cleidocranial Dysostosis

Abnormal bone remodeling activity of dental follicle cells from a cleidocranial dysplasia patient.

Abnormal bone remodelling activity of dental follicle cells from a cleidocranial dysplasia patient

US science to pay price if station proceeds

Complex segregation analysis of deafness in Dalmatians.

AMPK regulates metabolism and survival in response to ionizing radiation.

RUNX2 Regulates Osteoblast Differentiation via the BMP4 Signaling Pathway

Eye dose monitoring of PET/CT workers.